Achieve Life Sciences (ACHV) Competitors $4.25 -0.14 (-3.19%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACHV vs. SGMO, RIGL, EBS, XOMA, CDXS, VNDA, LXRX, VSTM, RGLS, and AGENShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Sangamo Therapeutics (SGMO), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), XOMA (XOMA), Codexis (CDXS), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), Verastem (VSTM), Regulus Therapeutics (RGLS), and Agenus (AGEN). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Sangamo Therapeutics Rigel Pharmaceuticals Emergent BioSolutions XOMA Codexis Vanda Pharmaceuticals Lexicon Pharmaceuticals Verastem Regulus Therapeutics Agenus Achieve Life Sciences (NASDAQ:ACHV) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Does the media prefer ACHV or SGMO? In the previous week, Sangamo Therapeutics had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 20 mentions for Sangamo Therapeutics and 19 mentions for Achieve Life Sciences. Sangamo Therapeutics' average media sentiment score of 0.60 beat Achieve Life Sciences' score of 0.51 indicating that Sangamo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sangamo Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ACHV or SGMO more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. Achieve Life Sciences' return on equity of -108.30% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Achieve Life SciencesN/A -108.30% -65.20% Sangamo Therapeutics -257.87%-264.16%-107.24% Does the MarketBeat Community prefer ACHV or SGMO? Sangamo Therapeutics received 112 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 62.55% of users gave Sangamo Therapeutics an outperform vote. CompanyUnderperformOutperformAchieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% Sangamo TherapeuticsOutperform Votes44662.55% Underperform Votes26737.45% Which has more volatility and risk, ACHV or SGMO? Achieve Life Sciences has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Do analysts rate ACHV or SGMO? Achieve Life Sciences presently has a consensus target price of $14.80, suggesting a potential upside of 248.24%. Sangamo Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 241.46%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Achieve Life Sciences is more favorable than Sangamo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals hold more shares of ACHV or SGMO? 33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.0% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 2.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, ACHV or SGMO? Achieve Life Sciences has higher earnings, but lower revenue than Sangamo Therapeutics. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAchieve Life SciencesN/AN/A-$29.82M-$1.13-3.76Sangamo Therapeutics$176.23M2.43-$257.83M-$0.75-2.73 SummaryAchieve Life Sciences beats Sangamo Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Colonial Metals“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…>> YES! Send Me My FREE Gold Guide! Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$146.16M$2.19B$5.12B$8.72BDividend YieldN/A0.72%5.18%4.07%P/E Ratio-3.762.4372.8114.16Price / SalesN/A39.681,250.2081.71Price / CashN/A14.7440.7036.03Price / Book4.672.996.455.94Net Income-$29.82M$29.98M$119.73M$225.73M7 Day Performance-8.21%-11.24%-5.13%-1.34%1 Month Performance-15.84%-12.49%-2.71%1.15%1 Year Performance-19.81%-20.97%31.08%24.02% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences1.576 of 5 stars$4.25-3.2%$14.80+248.2%-17.3%$146.16MN/A-3.7620Analyst ForecastAnalyst RevisionNews CoverageSGMOSangamo Therapeutics2.2761 of 5 stars$2.05-4.7%$7.00+241.5%+484.5%$427.73M$176.23M-2.73480Earnings ReportAnalyst ForecastAnalyst RevisionRIGLRigel Pharmaceuticals3.9843 of 5 stars$24.10-12.2%$31.30+29.9%+197.5%$424.52M$116.88M172.16147Analyst ForecastNews CoverageEBSEmergent BioSolutions4.4029 of 5 stars$7.72-16.7%$14.00+81.3%+264.2%$418.30M$1.09B-1.881,600Analyst UpgradeGap DownXOMAXOMA4.4351 of 5 stars$30.21+1.1%$78.50+159.8%+104.1%$355.96M$4.76M-8.6810Insider SellingShort Interest ↓CDXSCodexis4.2611 of 5 stars$3.88+3.7%$8.33+114.8%+88.3%$315.75M$64.45M-4.46250Analyst ForecastNews CoverageHigh Trading VolumeVNDAVanda Pharmaceuticals4.2954 of 5 stars$5.00-2.0%$15.50+210.0%+47.9%$291.54M$192.64M-17.86203Analyst ForecastLXRXLexicon Pharmaceuticals2.0164 of 5 stars$0.98-7.6%$6.00+515.3%-8.0%$240.13M$1.20M-1.30285Earnings ReportAnalyst ForecastAnalyst RevisionVSTMVerastem2.9685 of 5 stars$3.99-3.4%$14.57+265.2%-34.0%$177.58M$2.60M-1.2550RGLSRegulus Therapeutics2.7539 of 5 stars$1.43-4.7%$10.80+655.2%+5.1%$93.66MN/A-1.3430Short Interest ↓Analyst RevisionNews CoverageAGENAgenus3.8222 of 5 stars$2.72-1.8%$10.00+267.6%-80.6%$63.81M$160.43M-0.24389Analyst ForecastShort Interest ↓Analyst Revision Related Companies and Tools Related Companies SGMO Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives CDXS Alternatives VNDA Alternatives LXRX Alternatives VSTM Alternatives RGLS Alternatives AGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHV) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACHV Stock Alerts